Polyplus-transfection initiates construction of Vectura, a new 4,000m2 facility
July 23, 2021
The leading biotechnology company that supports the gene and cell therapy market by supplying innovative transfection solutions, announced the construction of Vectura, a new state of the art 4,000m2 facility.
The new facility is built to enable Polyplus-transfection® to continue to cater for the exponential growth in demand for raw materials for ATMP development and manufacturing. Following completion of the facility, Polyplus will be able to meet the expectations of the gene and cell therapy market moving from late-stage clinical development into commercialization as well as ongoing increases in R&D and preclinical gene therapy development. The facility will also house Polyplus-transfection®’s head office, managing its international operations and delivery of transfection reagents to cell and gene therapy organizations around the globe.
The new facility will fulfill several immediate priorities for Polyplus. These priorities include doubling its headcount both in its gene and cell therapy transfection reagent manufacturing and development departments. It will also provide significant additional manufacturing capacity for ex vivo and in vivo therapy products. This will increase Polyplus’ production capacity to manufacture and deliver transfection solutions to target a wide range of diseases globally. In the new facility, R&D and laboratory space will increase by over 300%.